Thus, RAD51D mutation carriers may benefit from PARP inhibitors as do patients with inactivating mutations in other HR genes, such as BRCA1, BRCA2, and PALB2. Loveday et al (2011) showed in tumour cells that short interfering RNAi reagents targeting RAD51D caused sensitivity to the PARP inhibitor olaparib, similar to the effect seen when BRCA1 or BRCA2 are silenced. This evidence concerns the gene PALB2 and neoplasm.